Therefore, the V1B receptor antagonist is expected to ameliorate the abnormalities of the HPA axis observed in depression, and consequently, to improve depressive symptoms in certain subpopulations of depressed individuals with impaired HPA axis function. This evidence concerns the gene AVPR1B and depressive disorder.